临床试验

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT：NCT05977036 · RECRUITING

NCT编号NCT05977036

状态RECRUITING

开始日期2024-09-25

完成时间2035-09-30

SponsorWashington University School of Medicine (OTHER)

First posted2023-08-04

Last updated2026-10-09

简要摘要

This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with hormone receptor (HR) positive, HER-2 negative metastatic or unresectable breast cancer receiving first-line or second-line treatment.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。